On the morning of April 24, 2025, Ben Tre Pharmaceutical Joint Stock Company (Bepharco) successfully held its 2024 Annual General Meeting of Shareholders in Ben Tre Province. The event was attended by shareholders, the company’s Board of Directors, and guest delegates from financial partner organizations such as MB Bank and VietinBank.

Agreement on important matters – Clear direction for 2025

At the General Meeting, shareholders discussed, contributed ideas, and unanimously approved several important items, including:

• Report on the 2024 activities and the 2025 plan of the Board of Directors
• 2024 report from the Audit Committee
• Evaluation report from the Independent Board Members
• Report summarizing activities and business plans for 2025 from the CEO
• Other issues within the scope of the General Meeting’s decision-making authority

These items not only summarize the achievements of the past year but also reflect the leadership’s commitment to innovation and sustainable development in the upcoming phase, with the strong support of all shareholders."

High attendance rate – Unity for common development

The General Meeting recorded the participation of 20 valid shareholders/representatives (holding 6,151,131 shares), along with 49 valid proxy shareholders (representing 8,182,645 shares). The total number of shares with voting rights at the General Meeting was 14,333,596, equivalent to 69.82% of the total shares with voting rights of the Company. This ratio not only fully meets the legal requirements for organizing the General Meeting, but also demonstrates the high sense of responsibility and the strong commitment of shareholders to the sustainable development of the Company.

The meeting was a success – a foundation for a year full of expectations

At 11:30 AM, Mr. Nguyễn Khắc Hanh – Chairman of the Board of Directors, on behalf of the Presidium, declared the closing of the General Shareholders’ Meeting, marking the end of a successful, transparent session that ensured the rights of shareholders and complied with the legal regulations and the Company’s Charter.

The meeting was not only an opportunity to review the results of the past fiscal year and set future directions, but also an important milestone showcasing the strong bond and collaboration between shareholders and strategic partners. With this trust and support, Bepharco enters 2025 with a spirit of innovation, high determination, and a desire to achieve breakthrough development goals.

With the trust and support of the shareholder community, Ben Tre Pharmaceutical Joint Stock Company enters 2025 with a spirit of innovation, high determination, and a strong desire to achieve breakthrough development goals.